文献速递慢病管理预防保健、筛查与疫苗

镰状细胞病的共同管理、医疗利用与羟基脲使用

Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
PubMed 文献 · J Am Board Fam Med · 2020-01-01

本研究分析北卡罗来纳州医疗补助计划中2790例镰状细胞病患者的急性照护利用、与共同管理相关的患者因素及羟基脲依从性。仅34.82%患者接受共同管理,年龄是共同管理的最强影响因素(AUC=0.599),仅32.24%患者有至少1次羟基脲处方,年龄是羟基脲良好依从性的最强预测因素(AUC=0.6503),共同管理的预测作用有限(AUC=0.5615)。

要点

  • 仅34.82%的镰状细胞病患者接受共同管理,1-9岁组比例最高(44.88%)。
  • 仅32.24%患者有至少1次羟基脲处方,年龄是良好依从性的最强预测因素。
  • 共同管理可预测羟基脲依从性,但预测作用有限(AUC=0.5615)。

核心结论

  • 共同管理是预测羟基脲依从性的一个因素,但需进一步研究确定增加依从性和减少急性照护利用所需的共同管理频率和组成部分。

研究设计与样本

  • 回顾性分析2016年3月至2017年2月北卡罗来纳州医疗补助计划中2790例1至65岁以上、入组至少1个月的镰状细胞病患者的数据。
  • 共同管理定义为研究期间每位患者至少1次初级保健就诊和1次血液科就诊。

主要发现

  • 仅34.82%的样本接受共同管理,1-9岁组为44.88%,10-17岁组为39.22%,31-45岁组为30.26%,65岁以上组为18.75%。
  • 年龄对是否接受共同管理的影响最大(AUC=0.599)。
  • 仅32.24%的样本有至少1次羟基脲处方。
  • 年龄是羟基脲良好依从性的最强预测因素(AUC=0.6503),共同管理的预测作用有限(AUC=0.5615)。

关键数值与推荐

  • 共同管理定义为研究期间每位患者至少1次初级保健就诊和1次血液科就诊。

临床怎么用

  • 在镰状细胞病管理中应关注年龄相关的照护差异,年轻患者共同管理比例较高,而成年及老年患者较低。
  • 提高羟基脲处方率和依从性需考虑年龄因素,共同管理可能有一定作用但预测力有限。

局限性

  • 本研究为回顾性分析,仅基于北卡罗来纳州医疗补助计划数据,结论外推需谨慎。
  • 共同管理的定义仅基于就诊次数,未考虑共同管理的频率和具体组成部分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sickle-cell disease (SCD) causes significant morbidity, premature mortality, and high disease burden, resulting in frequent health care use. Comanagement may improve utilization and patient adherence with treatments such as Hydroxyurea. The purpose of this study was to describe acute-care utilization in Medicaid-enrolled patients with SCD, patient factors associated with comanagement, and adherence to Hydroxyurea. METHODS: Data from 2790 patients diagnosed with SCD, age 1 to 65+ years, enrolled at least 1 month in North Carolina Medicaid between March 2016 and February 2017, were analyzed. Outpatient visits were categorized as primary care, hematologist, and nonhematologist specialist. Nurse practitioners or physician assistants with unidentified specialty type or family practice were categorized separately. Comanagement was defined as a minimum of 1 primary care and 1 hematologist visit/patient during the study period. RESULTS: There were notable age-related differences in utilization of health care services. Only 34.82% of the sample was comanaged. Comanagement was higher in the 1-to-9-year-old (44.88%) and 10-to-17-year-old groups (39.22%) versus the 31-to-45-year-old (30.26%) and 65+-year-old (18.75%) age groups. Age had the greatest influence (AUC = 0.599) on whether or not a patient was comanaged. Only a third of the sample (32.24%) had at least 1 Hydroxyurea (HU) prescription. Age was the most predictive factor of good HUadherence (AUC = 0.6503). Prediction by comanagement was minimal with an AUC = 0.5615. CONCLUSION: Comanagement was a factor in predicting HUadherence, but further studies are needed to identify the frequency and components of comanagement needed to increase adherence and reduce acute care utilization.

来源:J Am Board Fam Med,查看原文。版权归原作者所有。

引用

  1. Crego N, Douglas C, Bonnabeau E, et al. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use. J Am Board Fam Med. 2020. PMID: 31907250. doi:10.3122/jabfm.2020.01.190143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。